Maraviroc is a CCR5 co-receptor antagonist used with other antiretroviral medications to treat CCR5-tropic HIV-1 infection. Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and...
- Mechanism
- Curator reviewed
Maraviroc is an entry inhibitor and works by blocking HIV from entering human cells. Specifically maraviroc is a selective, slowly reversible, small molecule antagonist of the interaction between human CCR5 and HIV-1 gp120. Maraviroc selectively binds to the human chemokine receptor CCR5 present on the membrane of CD4 cells (T-cells), preventing the interaction of HIV-1 gp120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells.
- Primary indication
- Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg.Curator reviewed · 3 structured indications
- Formula / weight
- C29H41F2N5O · 513.6655 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2007 · European Union, 2016
- Brand names
Resolves to
GSNHKUDZZFZSJB-QYOOZWMWSA-NSMILESCC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Maraviroc, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account